Evidence map›Paper›PMID 32850823›Full record

ArticleFrontiers in cell and developmental biology2020

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia.

Mo Chen, Chenyi Ye, Jianing Zhu, Peiyu Zhang, Yujie Jiang, Xiaoyong Lu, Huaxiang Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Clinical Potential of Himalayan HerbMolecules (Basel, Switzerland) · 2022
    Review
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mo ChenDepartment of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chenyi YeDepartment of Orthopedic, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jianing ZhuDepartment of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Peiyu ZhangDepartment of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yujie JiangDepartment of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xiaoyong LuDepartment of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Huaxiang WuDepartment of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Second Affiliated Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bergenin is a C-glucoside of 4-

Indexed as

ABCG2bergeninhyperuricemiaSLC2A9urate-lowering therapeutic

Identifiers

PMID32850823
PMCPMC7403512
OpenAlexW3046138483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.